Patents by Inventor Olivier Nolan-Stevaux

Olivier Nolan-Stevaux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-STEAP1 ANTIGEN-BINDING PROTEIN
    Publication number: 20230159656
    Abstract: The disclosure provides novel antigen-binding proteins that bind STEAP1 and methods of use.
    Type: Application
    Filed: November 10, 2022
    Publication date: May 25, 2023
    Inventors: Olivier Nolan-Stevaux, Cong Li, Christopher M. Murawsky, Benjamin M. Alba, Neeraj Jagdish Agrawal, Kevin Graham, Jennitte LeAnn Stevens
  • ANTI-CCR8 ANTIBODIES AND USES THEREOF
    Publication number: 20220403037
    Abstract: The present invention provides anti-CCR8 antibodies and antigen-binding fragments thereof, and methods of making and using said anti-CCR8 antibodies and antigen-binding fragments thereof.
    Type: Application
    Filed: June 2, 2022
    Publication date: December 22, 2022
    Inventors: NATHAN WILLIAM PIERCE, AGNIESZKA KIELCZEWSKA, WENTAO CHEN, OLIVIER NOLAN-STEVAUX, DARREN L. BATES, LISA WINKEL, CHRISTOPH DAHLHOFF, TOBIAS RAUM, CLAUDIA BLUEMEL, JONAS KARL-JOSEF HONER
  • Anti-STEAP1 antigen-binding protein
    Patent number: 11530274
    Abstract: The disclosure provides novel antigen-binding proteins that bind STEAP1 and methods of use.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: December 20, 2022
    Assignees: AMGEN INC., XENCOR, INC.
    Inventors: Olivier Nolan-Stevaux, Cong Li, Christopher M. Murawsky, Benjamin M. Alba, Neeraj Jagdish Agrawal, Kevin Graham, Jennitte LeAnn Stevens, Gregory Moore
  • ANTIBODY CONSTRUCTS FOR CD70 AND CD3
    Publication number: 20210284748
    Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human CD70 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
    Type: Application
    Filed: October 29, 2020
    Publication date: September 16, 2021
    Inventors: Tobias Raum, Claudia Blümel, Wibke Deisting, Patrick Hoffmann, Ralf Lutterbüse, Elisabeth Nahrwold, Olivier Nolan-Stevaux, Marc Panzer
  • CHIMERIC RECEPTORS TO STEAP1 AND METHODS OF USE THEREOF
    Publication number: 20210277148
    Abstract: Antigen binding molecules, chimeric receptors, and engineered immune cells to STEAP1 are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the STEAP1 antigen binding molecules and engineered immune cells.
    Type: Application
    Filed: July 17, 2019
    Publication date: September 9, 2021
    Applicant: AMGEN INC.
    Inventor: Olivier NOLAN-STEVAUX
  • ANTI-STEAP1 ANTIGEN-BINDING PROTEIN
    Publication number: 20210179731
    Abstract: The disclosure provides novel antigen-binding proteins that bind STEAP1 and methods of use.
    Type: Application
    Filed: July 2, 2019
    Publication date: June 17, 2021
    Inventors: Olivier Nolan-Stevaux, Cong Li, Christopher M. Murawsky, Benjamin M. Alba, Neeraj Jagdish Agrawal, Kevin Graham, Jennitte LeAnn Stevens, Gregory Moore
  • Antibody constructs for CD70 and CD3
    Patent number: 10851170
    Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human CD70 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: December 1, 2020
    Assignees: AMGEN RESEARCH (MUNICH) GMBH, AMGEN INC.
    Inventors: Tobias Raum, Claudia Blümel, Wibke Deisting, Patrick Hoffmann, Ralf Lutterbüse, Elisabeth Nahrwold, Olivier Nolan-Stevaux, Marc Panzer
  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CD38
    Publication number: 20180305465
    Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.
    Type: Application
    Filed: November 23, 2016
    Publication date: October 25, 2018
    Inventors: Jennitte Leann Stevens, Mercedesz Balazs, Olivier Nolan-Stevaux, Gregory Moore, John Desjarlais, Matthew J. Bernett, Seung Y. Chu, Rumana Rashid, Umesh Muchhal
  • ANTIBODY CONSTRUCTS FOR CD70 AND CD3
    Publication number: 20170129961
    Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human CD70 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
    Type: Application
    Filed: August 1, 2016
    Publication date: May 11, 2017
    Inventors: Tobias Raum, Claudia Blümel, Wibke Deisting, Patrick Hoffmann, Ralf Lutterbüse, Elisabeth Nahrwold, Olivier Nolan-Stevaux, Marc Panzer